Several clinical studies indicate that overexpression of inflammatory cytokines, such as IL-1, IL8, IL6 or CXCL1, correlates with cancer progression and decreased response to EGFR targeting therapy [25,27]. This evidence concerns the gene CXCL8 and cancer.